{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T21:56:04Z","timestamp":1784152564236,"version":"3.55.0"},"reference-count":95,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transfusion Medicine Reviews"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.tmrv.2022.06.001","type":"journal-article","created":{"date-parts":[[2022,6,9]],"date-time":"2022-06-09T22:05:46Z","timestamp":1654812346000},"page":"125-132","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2"],"prefix":"10.1016","volume":"36","author":[{"given":"Thierry","family":"Burnouf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Gathof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan M.","family":"Bloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9e","family":"Bazin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincenzo","family":"de Angelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gopal Kumar","family":"Patidar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rada M. Grubovic","family":"Rastvorceva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adaeze","family":"Oreh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruchika","family":"Goel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Rahimi-Levene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salwa","family":"Hindawi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arwa Z.","family":"Al-Riyami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"So-Osman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.tmrv.2022.06.001_bib0001","unstructured":"John Hopkins University of Medicine. Coronavirus COVID-19 global cases by the center for systems science and engineering at Johns Hopkins. 2022. Accessed from: https:\/\/coronavirus.jhu.edu\/map.html (Accessed at: July 18, 2022)."},{"key":"10.1016\/j.tmrv.2022.06.001_bib0002","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically Ill patients with COVID-19 with convalescent plasma","volume":"323","author":"Shen","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0003","doi-asserted-by":"crossref","first-page":"9490","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","volume":"117","author":"Duan","year":"2020","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1003872","article-title":"Access to and safety of COVID-19 convalescent plasma in the United States expanded access program: a national registry study","volume":"18","author":"Senefeld","year":"2021","journal-title":"PLoS Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0005","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1056\/NEJMoa2103784","article-title":"Early convalescent plasma for high-risk outpatients with Covid-19","volume":"385","author":"Korley","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0006","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/S0140-6736(21)00897-7","article-title":"Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0007","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1056\/NEJMoa2031893","article-title":"Convalescent plasma antibody levels and the risk of death from Covid-19","volume":"384","author":"Joyner","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0008","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.1038\/s41591-020-1088-9","article-title":"Convalescent plasma treatment of severe COVID-19: a propensity score-matched control study","volume":"26","author":"Liu","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0009","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.2021.18178","article-title":"Effect of convalescent plasma on organ support-free days in critically Ill patients with COVID-19: a randomized clinical trial","volume":"326","author":"Estcourt","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0010","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.1799","article-title":"Association of convalescent plasma therapy with survival in patients with hematologic cancers and COVID-19","author":"Thompson","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0011","doi-asserted-by":"crossref","DOI":"10.1128\/cmr.00200-21","article-title":"COVID-19 convalescent plasma and clinical trials: understanding conflicting outcomes","author":"Focosi","year":"2022","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2119657","article-title":"Early outpatient treatment for Covid-19 with convalescent plasma","author":"Sullivan","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0013","article-title":"Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review","volume":"5","author":"Piechotta","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0014","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1172\/JCI138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","volume":"130","author":"Bloch","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.transci.2020.102957","article-title":"Promoting access to COVID-19 convalescent plasma in low- and middle-income countries","volume":"60","author":"Bloch","year":"2021","journal-title":"Transfus Apher Sci"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0016","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1111\/vox.12970","article-title":"Guidance for the procurement of COVID-19 convalescent plasma: differences between high- and low-middle-income countries","volume":"116","author":"Bloch","year":"2021","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0017","doi-asserted-by":"crossref","DOI":"10.1016\/j.xcrm.2021.100255","article-title":"Complete map of SARS-CoV-2 RBD mutations that escape the monoclonal antibody LY-CoV555 and its cocktail with LY-CoV016","volume":"2","author":"Starr","year":"2021","journal-title":"Cell Reports Medicine"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0018","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/s41591-021-01285-x","article-title":"SARS-CoV-2 501Y.V2 escapes neutralization by South African COVID-19 donor plasma","volume":"27","author":"Wibmer","year":"2021","journal-title":"Nature Medicine"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0019","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S0140-6736(22)00101-5","article-title":"Hyperimmune immunoglobulin for hospitalised patients with COVID-19 (ITAC): a double-blind, placebo-controlled, phase 3, randomised trial","volume":"399","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0020","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-020-2571-7","article-title":"Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike","volume":"584","author":"Liu","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0021","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.cell.2020.07.012","article-title":"The impact of mutations in SARS-CoV-2 spike on viral infectivity and antigenicity","volume":"182","author":"Li","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0022","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1111\/trf.16378","article-title":"Production of anti-SARS-CoV-2 hyperimmune globulin from convalescent plasma","volume":"61","author":"Vandeberg","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0023","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1056\/NEJMoa2033700","article-title":"Early high-titer plasma therapy to prevent severe Covid-19 in older adults","volume":"384","author":"Libster","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0024","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1111\/trf.16291","article-title":"Longitudinal analysis of SARS-CoV-2 antibodies in 8000 US first-time convalescent plasma donations","volume":"61","author":"Karbiener","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0025","unstructured":"An EU programme of COVID-19 convalescent plasma collection and transfusion. Guidance on collection, testing, processing, storage, distribution and monitored use. https:\/\/ec.europa.eu\/health\/system\/files\/2021-03\/guidance_plasma_covid19_en_0.pdf. 2021. Accessed from: https:\/\/ec.europa.eu\/health\/sites\/default\/files\/blood_tissues_organs\/docs\/guidance_plasma_covid19_en.pdf (Accessed at: June 1, 2022)"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0026","unstructured":"Investigational COVID-19 convalescent plasma-Guidance for Industry. Accessed from: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/investigational-covid-19-convalescent-plasma#:\u223c:text=Investigational%20COVID%2D19%20Convalescent%20Plasma%20Guidance%20for%20Industry%20January%202022&text=FDA%20plays%20a%20critical%20role,(COVID%2D19)%20pandemic. 2021. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/investigational-covid-19-convalescent-plasma (Accessed at: June 1, 2022)."},{"key":"10.1016\/j.tmrv.2022.06.001_bib0027","unstructured":"ECDC-Suspected adverse reactions to COVID-19 vaccination and the safety of substances of human origin. Accessed from: https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Suspected-adverse-reactions-to-COVID-19-vaccination-and-safety-of-SoHO.pdf (Accessed at: March 11, 2022), 2021."},{"key":"10.1016\/j.tmrv.2022.06.001_bib0028","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1111\/vox.13108","article-title":"Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology","volume":"116","author":"Yonemura","year":"2021","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0029","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2217\/imt-2020-0263","article-title":"Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma","volume":"13","author":"Ali","year":"2021","journal-title":"Immunotherapy"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0030","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10067-019-04832-7","article-title":"Transfusion-related acute lung injury (TRALI) after intravenous immunoglobulins: French multicentre study and literature review","volume":"39","author":"Baudel","year":"2020","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0031","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1111\/trf.16401","article-title":"Exponential increase in neutralizing and spike specific antibodies following vaccination of COVID-19 convalescent plasma donors","volume":"61","author":"Vickers","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0032","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/vox.13094","article-title":"High-titre anti-SARS-CoV-2 convalescent plasma donation after donors' vaccination","volume":"116","author":"Romon","year":"2021","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0033","doi-asserted-by":"crossref","first-page":"jiab482","DOI":"10.1093\/infdis\/jiab482","article-title":"Plasma from post-COVID-19 and COVID-19-Vaccinated Donors Results in Highly Potent SARS-CoV-2 Neutralization by Intravenous Immunoglobulins","author":"Karbiener","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0034","doi-asserted-by":"crossref","first-page":"918","DOI":"10.3390\/vaccines9080918","article-title":"mRNA vaccines enhance neutralizing immunity against SARS-CoV-2 variants in convalescent and ChAdOx1-primed subjects","volume":"9","author":"Fabricius","year":"2021","journal-title":"Vaccines"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0035","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1056\/NEJMc2103825","article-title":"SARS-CoV-2 antibody response in persons with past natural infection","volume":"385","author":"Anichini","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0036","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.kint.2021.06.025","article-title":"Humoral response after 3 doses of the BNT162b2 mRNA COVID-19 vaccine in patients on hemodialysis","volume":"100","author":"Ducloux","year":"2021","journal-title":"Kidney Int"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0037","doi-asserted-by":"crossref","first-page":"97-109 e5","DOI":"10.1016\/j.chom.2021.12.004","article-title":"Strong humoral immune responses against SARS-CoV-2 Spike after BNT162b2 mRNA vaccination with a 16-week interval between doses","volume":"30","author":"Tauzin","year":"2022","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0038","article-title":"Robust spike antibody responses and increased reactogenicity in seropositive individuals after a single dose of SARS-CoV-2 mRNA vaccine","author":"Krammer","year":"2021","journal-title":"MedRxiv"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0039","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1001\/jama.2021.3341","article-title":"Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2","volume":"325","author":"Saadat","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0040","doi-asserted-by":"crossref","first-page":"e171","DOI":"10.1016\/S2666-5247(21)00060-4","article-title":"Convalescent plasma from people vaccinated after COVID-19 infection","volume":"2","author":"Jabal","year":"2021","journal-title":"Lancet Microbe"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0041","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.3201\/eid2607.200841","article-title":"Severe acute respiratory syndrome coronavirus 2\u2212 specific antibody responses in coronavirus disease patients","volume":"26","author":"Okba","year":"2020","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0042","article-title":"Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset","volume":"2","author":"Anand","year":"2021","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0043","doi-asserted-by":"crossref","first-page":"5699","DOI":"10.1016\/j.cell.2021.10.011","article-title":"Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine","volume":"184","author":"Payne","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0044","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(21)00432-3","article-title":"Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0045","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1056\/NEJMc2103916","article-title":"Antibody persistence through 6 months after the second dose of mRNA-1273 vaccine for Covid-19","volume":"384","author":"Doria-Rose","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0046","unstructured":"Convalescent Plasma EUA Letter of Authorization. Accessed from: https:\/\/www.fda.gov\/media\/141477\/download (Accessed at: June 1, 2022)."},{"key":"10.1016\/j.tmrv.2022.06.001_bib0047","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1002\/jmv.26770","article-title":"Performance and feasibility of universal PCR admission screening for SARS-CoV-2 in a German tertiary care hospital","volume":"93","author":"Kr\u00fcger","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0048","doi-asserted-by":"crossref","first-page":"2837","DOI":"10.1111\/trf.16600","article-title":"Comparability of six different immunoassays measuring SARS-CoV-2 antibodies with neutralizing antibody levels in convalescent plasma: from utility to prediction","volume":"61","author":"Lamikanra","year":"2021","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0049","doi-asserted-by":"crossref","first-page":"6728","DOI":"10.1172\/JCI141206","article-title":"Convalescent plasma anti-SARS-CoV-2 spike protein ectodomain and receptor-binding domain IgG correlate with virus neutralization","volume":"130","author":"Salazar","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0050","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1111\/trf.16065","article-title":"Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: preliminary lessons from a voluntary convalescent donor program","volume":"60","author":"Wendel","year":"2020","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0051","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/S0140-6736(21)00527-4","article-title":"WHO international standard for anti-SARS-CoV-2 immunoglobulin","volume":"397","author":"Kristiansen","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0052","doi-asserted-by":"crossref","first-page":"ofab220","DOI":"10.1093\/ofid\/ofab220","article-title":"Evaluation of a commercial culture-free neutralization antibody detection kit for severe acute respiratory syndrome-related coronavirus-2 and comparison with an antireceptor-binding domain enzyme-linked immunosorbent assay","volume":"8","author":"Papenburg","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0053","doi-asserted-by":"crossref","first-page":"e81","DOI":"10.1016\/S2666-5247(21)00307-4","article-title":"WHO international standard for SARS-CoV-2 antibodies to determine markers of protection","volume":"3","author":"Zhu","year":"2022","journal-title":"Lancet Microbe"},{"issue":"2","key":"10.1016\/j.tmrv.2022.06.001_bib0054","doi-asserted-by":"crossref","first-page":"e00765","DOI":"10.1128\/mBio.00765-21","article-title":"Markers of polyfunctional SARS-CoV-2 antibodies in convalescent plasma","volume":"12","author":"Natarajan","year":"2021","journal-title":"mBio"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0055","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41591-021-01488-2","article-title":"Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial","volume":"27","author":"B\u00e9gin","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0056","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1016\/j.immuni.2021.08.015","article-title":"Live imaging of SARS-CoV-2 infection in mice reveals that neutralizing antibodies require Fc function for optimal efficacy","volume":"54","author":"Ullah","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0057","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact Fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0058","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110368","article-title":"A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection","volume":"38","author":"Beaudoin-Bussieres","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0059","doi-asserted-by":"crossref","first-page":"6141","DOI":"10.1172\/JCI142004","article-title":"Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population","volume":"130","author":"Klein","year":"2020","journal-title":"J Clin Invest"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0247640","article-title":"Presence of antibody-dependent cellular cytotoxicity (ADCC) against SARS-CoV-2 in COVID-19 plasma","volume":"16","author":"Tso","year":"2021","journal-title":"PLoS One"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0061","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/s41591-020-0897-1","article-title":"Antibody responses to SARS-CoV-2 in patients with COVID-19","volume":"26","author":"Long","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0062","doi-asserted-by":"crossref","first-page":"2588","DOI":"10.1182\/blood.2020008367","article-title":"Waning of SARS-CoV-2 RBD antibodies in longitudinal convalescent plasma samples within 4 months after symptom onset","volume":"136","author":"Perreault","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0063","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1038\/s41564-020-00813-8","article-title":"Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans","volume":"5","author":"Seow","year":"2020","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0064","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.108790","article-title":"Major role of IgM in the neutralizing activity of convalescent plasma against SARS-CoV-2","volume":"34","author":"Gasser","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0065","article-title":"Cross-sectional evaluation of humoral responses against SARS-CoV-2 spike","volume":"1","author":"Pr\u00e9vost","year":"2020","journal-title":"Cell Rep Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0066","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1093\/infdis\/jiaa784","article-title":"Role of immunoglobulin M and A antibodies in the neutralization of severe acute respiratory syndrome coronavirus 2","volume":"223","author":"Klingler","year":"2021","journal-title":"J Infect Dis"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0067","unstructured":"Guide to the preparation, use and quality assurance of blood components. Accessed from: https:\/\/www.edqm.eu\/en\/blood-guide#:~:text=GTS%20Working%20Group-,The%20Guide%20to%20the%20preparation%2C%20use%20and%20quality%20assurance%20of,requirements%20for%20blood%20components%20in. Council of Europe; 2020. Accessed at: July 18, 2022"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0068","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1423-0410.2009.01226.x","article-title":"Intravenous immunoglobulin G: trends in production methods, quality control and quality assurance","volume":"98","author":"Radosevich","year":"2010","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0069","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1016\/j.biologicals.2014.04.002","article-title":"Quantifying the thrombogenic potential of human plasma-derived immunoglobulin products","volume":"42","author":"Germishuizen","year":"2014","journal-title":"Biologicals"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0070","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1054\/blre.2000.0129","article-title":"Reducing the risk of infection from plasma products: specific preventative strategies","volume":"14","author":"Burnouf","year":"2000","journal-title":"Blood Rev"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0071","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0887-7963(03)00038-5","article-title":"Risks associated with the use of intravenous immunoglobulin","volume":"17","author":"Pierce","year":"2003","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0072","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0073","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0074","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.tmrv.2006.11.001","article-title":"Modern plasma fractionation","volume":"21","author":"Burnouf","year":"2007","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0075","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40259-016-0192-3","article-title":"Reduction of isoagglutinin in intravenous immunoglobulin (IVIG) using blood group A- and B-specific immunoaffinity chromatography: industry-scale assessment","volume":"30","author":"Gerber","year":"2016","journal-title":"BioDrugs"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0076","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s40259-017-0222-9","article-title":"Biological safety of a highly purified 10% liquid intravenous immunoglobulin preparation from human plasma","volume":"31","author":"Goussen","year":"2017","journal-title":"BioDrugs"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0077","first-page":"467","article-title":"Process steps for the fractionation of immunoglobulin (Ig) G depleted of IgA, isoagglutinins, and devoid of in vitro thrombogenicity","volume":"19","author":"Cheng","year":"2021","journal-title":"Blood Transfus"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0078","first-page":"334","article-title":"Contact-activated factors: contaminants of immunoglobulins preparations with coagulant and vasoactive properties","volume":"96","author":"Alving","year":"1980","journal-title":"J Lab Clin Med"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0079","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/j.1423-0410.2011.01502.x","article-title":"Identification of kallikrein and FXIa as impurities in therapeutic immunoglobulins: implications for the safety and control of intravenous blood products","volume":"102","author":"Etscheid","year":"2012","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0080","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1002\/1096-8652(200009)65:1<30::AID-AJH5>3.0.CO;2-J","article-title":"Coagulation factor XI is a contaminant in intravenous immunoglobulin preparations","volume":"65","author":"Wolberg","year":"2000","journal-title":"Am J Hematol"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0081","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1111\/j.1537-2995.2012.03589.x","article-title":"Immune globulins and thrombotic adverse events as recorded in a large administrative database in 2008 through 2010","volume":"52","author":"Daniel","year":"2012","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0082","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1007\/BF00919386","article-title":"Long-term use of IgA-depleted intravenous immunoglobulin in immunodeficient subjects with anti-IgA antibodies","volume":"13","author":"Cunningham-Rundles","year":"1993","journal-title":"J Clin Immunol"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0083","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1111\/trf.12796","article-title":"The entity of immunoglobulin A-related anaphylactic transfusion reactions is not evidence based","volume":"55","author":"Sandler","year":"2015","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0084","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1038\/s41586-020-2538-8","article-title":"A perspective on potential antibody-dependent enhancement of SARS-CoV-2","volume":"584","author":"Arvin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0085","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.tmrv.2020.04.002","article-title":"COVID-19 convalescent plasma: now is the time for better science","volume":"34","author":"Dzik","year":"2020","journal-title":"Transfus Med Rev"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0086","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.mayocp.2020.06.028","article-title":"Safety update: COVID-19 convalescent plasma in 20,000 hospitalized patients","volume":"95","author":"Joyner","year":"2020","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0087","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(22)00112-X","article-title":"High-dose immunoglobulins from convalescent donors for patients hospitalised with COVID-19","volume":"399","author":"So-Osman","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0088","unstructured":"Accessed from: https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04910269?cond=NCT04910269&draw=2&rank=1, 2022."},{"key":"10.1016\/j.tmrv.2022.06.001_bib0089","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0003501","article-title":"Minipool caprylic acid fractionation of plasma using disposable equipment: a practical method to enhance immunoglobulin supply in developing countries","volume":"9","author":"El-Ekiaby","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0090","doi-asserted-by":"crossref","first-page":"3019","DOI":"10.1111\/trf.14301","article-title":"A randomized multicenter study: safety and efficacy of mini-pool intravenous immunoglobulin versus standard immunoglobulin in children aged 1-18 years with immune thrombocytopenia","volume":"57","author":"Elalfy","year":"2017","journal-title":"Transfusion"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0091","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100926","article-title":"Hyperimmune anti-COVID-19 IVIG (C-IVIG) treatment in severe and critical COVID-19 patients: a phase I\/II randomized control trial","volume":"36","author":"Ali","year":"2021","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0092","unstructured":"WHO Action framework to advance universal access to safe, effective and quality assured blood products 2020 - 2023. Accessed from: https:\/\/www.who.int\/news\/item\/19-02-2020-who-action-framework-to-advance-universal-access-to-safe-effective-and-quality-assured-blood-products-2020-2023. Geneva: 2020."},{"key":"10.1016\/j.tmrv.2022.06.001_bib0093","unstructured":"Guidance on increasing supplies of plasma-derived medicinal products in low- and middle-income countries through fractionation of domestic plasma. Accessed from: https:\/\/www.who.int\/publications\/i\/item\/9789240021815. 2021. (Accessed at: June 1, 2022)."},{"key":"10.1016\/j.tmrv.2022.06.001_bib0094","doi-asserted-by":"crossref","DOI":"10.1111\/vox.13263","article-title":"Stepwise access to safe plasma proteins in resource-constrained countries: local production and pathways to fractionation-report of an international society of blood transfusion workshop","author":"Burnouf","year":"2022","journal-title":"Vox Sang"},{"key":"10.1016\/j.tmrv.2022.06.001_bib0095","unstructured":"WHO model lists of essential medicines WHO model list of essential medicines: 21st list 2019. Geneva: World Health Organization. Accessed from: https:\/\/apps.who.int\/iris\/handle\/10665\/325771. 2019. (Accessed at: June 1, 2022)."}],"container-title":["Transfusion Medicine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000219?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0887796322000219?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:19:47Z","timestamp":1760138387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0887796322000219"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":95,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0887796322000219"],"URL":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.06.001","relation":{},"ISSN":["0887-7963"],"issn-type":[{"value":"0887-7963","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Production and Quality Assurance of Human Polyclonal Hyperimmune Immunoglobulins Against SARS-CoV-2","name":"articletitle","label":"Article Title"},{"value":"Transfusion Medicine Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.tmrv.2022.06.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}